All trading involves risk. Contracts for Difference (CFDs) are complex instruments and may not be suitable for all investors. Please refer to Risk Disclosure and Risk Fact Sheet on Capital.com/en-sg.
Open platformOpen platform

Natera Partners With Incyte on Phase II Colorectal Cancer Study

By Public Technologies
  • Natera entered a clinical collaboration with Incyte for a phase II colorectal cancer study.
  • The trial will evaluate Incyte’s investigational bispecific immunotherapy INCA33890 in stage 2/3 patients who completed surgery and adjuvant chemotherapy.
  • Signatera testing will continue for up to 12 months following chemotherapy, with results incorporated as primary and secondary trial endpoints.
  • Patients testing positive for molecular residual disease without radiographic evidence of disease may qualify for enrollment and treatment.
  • The collaboration includes trial-matching services to identify eligible patients based on Signatera results.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611100700BIZWIRE_USPR_____20261110_BW610640) on November 10, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.